Picton Mahoney Asset Management »

Catalyst Pharmaceutical Partners shares owned by Picton Mahoney Asset Management

Quarter-by-quarter ownership of Catalyst Pharmaceutical Partners (CPRX) shares owned by Picton Mahoney Asset Management from 13F filings

Historical chart of Picton Mahoney Asset Management investment in Catalyst Pharmaceutical Partners

Tip: Access up to 7 years of quarterly data

All positions including Catalyst Pharmaceutical Partners held by Picton Mahoney Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Catalyst Pharmaceutical Partners by Picton Mahoney Asset Management

Quarter filed Position value Share count Share price at filing
2026-06-30 $8.6M 275k 31.43
2026-03-31 $1.4k 55 24.76
2025-12-31 $1.3k 55 23.35
2025-09-30 $999 55 18.18
2025-06-30 $999 55 18.18
2025-03-31 $999 55 18.18
2024-12-31 $999 55 18.18
2024-09-30 $999 55 18.18

More positions owned by Picton Mahoney Asset Management

Ishares Tr Iboxx Hi Yd Etf Put Option (HYG)
Rbc Cad (RY)
Toronto Dominion Bk Ont Com New (TD)
Ishares Tr Msci Usa Mmentm Put Option (MTUM)
Shopify Cl A Sub Vtg Shs Call Option (SHOP)
Canadian Pacific Kansas City (CP)
Invesco Qqq Tr Unit Ser 1 Call Option (QQQ)
Brookfield Corp Cl A Ltd Vt Sh (BN)
Vaneck Etf Trust Semiconductr Etf Put Option (SMH)
Enbridge (ENB)
Cenovus Energy Call Option (CVE)
Micron Technology Put Option (MU)
NVIDIA Corporation (NVDA)
Canadian Natural Resources (CNQ)
Celestica Call Option (CLS)

View all positions for Picton Mahoney Asset Management

Top funds holding Catalyst Pharmaceutical Partners

BlackRock
State Street Corporation
American Century Companies
Vanguard Capital Management
Dimensional Fund Advisors
Glazer Capital
Jpmorgan Chase & Co
Geode Capital Management
HBK Investments
Morgan Stanley
Vanguard Portfolio Management
Jupiter Topco
Qube Research & Technologies
Renaissance Technologies
Henderson Group

View all funds holding Catalyst Pharmaceutical Partners